

Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026

<https://marketpublishers.com/r/G66100CFD5EEN.html>

Date: April 2019

Pages: 1200

Price: US\$ 2,800.00 (Single User License)

ID: G66100CFD5EEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026'
Report Highlights:

Global Cell Therapy Market Opportunity: More Than US\$ 35 Billion by 2026

Cell Therapy Clinical Trial Insight by Indication, Company & Country

Global Cell Therapy Clinical Pipeline: 767 Cell Therapies

Globally Marketed Cell Therapies: 25 Cell Therapies

Maximum Number of Marketed Cell Therapies In USA: 15 Therapies

Price & Product Insight By Region/Country

Regional Analysis of the Cell Therapy Market

In recent years, there has been a steady increase in the interest shown in the cell therapy segment from big pharmaceutical, biotech and medical device companies. Earlier, the idea for altering a cell or a gene to cure or treat a disease was considered impossible. But with the ongoing advancements, it has now become possible in the treatment or cure of a disease with the help of cell therapy.

Cell therapies are still in the early stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that consideration will be given on how these therapies will be carried out and subsequently be delivered to the patients on a clinically relevancy scale.

Currently, there are more than 750 cell based therapies in clinical pipeline. Most of the cell therapies are in Preclinical phase followed by Phase-I clinical trials. Analysis of the pipeline shows that majority of the cell therapy products that are currently under development are targeted towards treatment of complex disease like cardiovascular disease, neural disease and cancer. More than 20 cell therapies are commercially available in the market. However, when it comes to marketed products, more than half of the products that are currently available are in the tissue and skin treatment segment such as Apligraf and Dermigraf.

Few cell therapy products such as Kymriah, Provenge and Yescarta have emerged as the most promising therapeutics of the decade with excellent result in treatment of various clinical indications, but the market remains widely untapped due to the high price tag.

The cell therapy technique finds wide usage in almost all types of therapeutic areas. However, majority of the cell therapy research is currently being done in the cancer, Neurological, Cardiovascular and Inflammatory segments due to their high mortality rate among the global population. Few cell therapy research is being done in the diabetic segment too where the aim is to develop an artificial pancreas using cell therapy which would work just like a natural pancreas.

Cell therapies will also have the potential to replace many risky, costly and invasive surgeries. For many disease conditions, such as diabetes, patients are required to take a prescription on a daily basis. A cell therapy approach will substantially reduce the healthcare costs of this disease by providing a one-time treatment. In the same way cell therapy approaches to pain management will also reduce the costs of opioid-based pain medications. Cell therapy, in combination with the recent advances in iPS cell generation and CRISPR-Cas 9, also has a great opportunity in the future.

The path towards the success for cell therapy will consist of a combination of scenarios that is being imagined for the cure of diseases and is hoped that these will definitely

come true in the near future. The advantages and risks of current cell therapy practices will improve translational success and accelerate clinical development of safe and efficient cell products in the future.

Contents

1. OVERVIEW OF CELL THERAPY

- 1.1 Introduction to Cell Therapy
- 1.2 History & Evolution of Cell Therapy

2. TYPES OF CELL THERAPY

- 2.1 Allogeneic Cell Therapy
- 2.2 Autologous Cell Therapy
- 2.3 Human Embryonic Stem Cell Therapy
- 2.4 Neural Stem Cell Therapy
- 2.5 Mesenchymal Stem Cell Therapy
- 2.6 Hematopoietic Stem Cell Transplantation

3. MECHANISM OF THERAPEUTIC ACTION IN CELL THERAPY

4. MANUFACTURING OF CELL THERAPIES

- 4.1 Models for Manufacturing Cell Therapies
- 4.2 Facilities for Good Manufacturing Practice

5. ADVANTAGES OF CELL THERAPY OVER CONVENTIONAL THERAPY

- 5.1 Anti-Aging with Cell Therapy
- 5.2 Addressing Other Diseases with Cell Therapy

6. PERSONALIZED CELL THERAPY

- 6.1 Overview of Personalized Cell Therapy
- 6.2 Personalized Cell Therapy Using Epigenetic Tools
- 6.3 Personalized Cell Therapy through Mesenchymal Stem Cells
- 6.4 Treatment of Parkinson's Disease through iPSCs
- 6.5 Case Study: Personalized Cell Therapy for Pulpitis Using Autologous Dental Pulp Stem Cells & Leukocyte Platelet Rich Fibrin

7. CELL THERAPY APPLICATION BY THERAPEUTIC AREAS

- 7.1 Cardiovascular Disease
- 7.2 Neurological Disorders
- 7.3 Inflammatory Diseases
- 7.4 Diabetes
- 7.5 Cancer

8. GLOBAL CELL THERAPY MARKET OUTLOOK

- 8.1 Current Market Scenario
- 8.2 Cell Therapy Market by Cell Source
 - 8.2.1 Induced Pluripotent Stem Cell (IPSCs)
 - 8.2.2 Bone Marrow
 - 8.2.3 Umbilical Cord Blood Derived Cells
- 8.3 Global Cell Therapy Clinical Pipeline (Company, Indication, Region) Overview

9. US - CELL THERAPY DOSAGE & COST ANALYSIS

- 9.1 Allocord
- 9.2 Laviv
- 9.3 Maci
- 9.4 Clevecord
- 9.5 Hemacord
- 9.6 Ducord
- 9.7 Provenge
- 9.8 HPC, Cord Blood (Clinimmune Labs, University of Colorado Cord Blood Bank)
- 9.9 HPC, Cord Blood (LifeSouth Community Blood Centers, Inc)
- 9.10 HPC, Cord Blood (Bloodworks)
- 9.11 HPC, Cord Blood (MD Anderson Cord Blood Bank)
- 9.12 Gintuit
- 9.13 Kymriah*
- 9.14 Yescarta*
- 9.15 Carticel

10. SOUTH KOREA - CELL THERAPY DOSAGE & COST ANALYSIS

- 10.1 Cartistem
- 10.2 Chondron
- 10.3 KeraHeal
- 10.4 Cellgram

10.5 Cure Skin Injection

11. AUSTRALIA, EUROPE & JAPAN - CELL THERAPY DOSAGE & COST ANALYSIS

11.1 Holoclar (Europe)

11.2 Yescarta (EU)

11.3 Kymriah (EU)

11.4 Temcell HS (Japan)

11.5 Chondrocytes-T-Ortho-ACI (Australia)

12. CELL THERAPY MARKET TRENDS: GEOGRAPHICALLY

12.1 US

12.2 South Korea

12.3 Europe

12.4 Japan

12.5 China

12.6 Rest of the World

12.6.1 Africa

12.6.2 Middle East

12.6.3 South America

13. ADVANCEMENTS IN CELL THERAPY

13.1 Drug Based Therapies Advancements in Chronic Lymphocytic Leukemia

13.2 Advances in Cytomegalovirus Infection Prevention & Treatment

13.3 Stem Cell Therapy for the Treatment of Parkinson's Disease

13.4 Stem Cell Therapy for the Treatment of Alzheimer's Disease

13.5 Treatment of Rheumatoid Arthritis via Stem Cell Therapy

13.6 Role of Stem Cell Therapy in Treating Infertility

13.7 Stem Cells for Eye Diseases

13.8 Cell Therapy for Stroke and Angina Pectoris

13.9 Stem Cell Therapy in Improving Wrinkles & Acne Scars

14. TREG CELLS – THE NEXT EDGE OF CELL THERAPY

14.1 Introduction to Treg Cell

14.2 Isolation & Expansion of Treg Cell

14.3 Mechanism of Action

14.4 Clinical Trials of Treg Cell Therapy

14.4.1 Adoptive Cell Therapy of Treg cells to Prevent GvHD

14.4.2 Adoptive Cell Therapy of Polyclonal & Alloantigen-specific Treg cells to Prevent Solid Organ Transplant Rejection

14.5 Treg Cell Therapy for the Treatment of Autoinflammatory & Autoimmune Diseases

14.5.1 Inflammatory Bowel Disease

14.5.2 Systemic Lupus Erythematosus

14.5.3 Autoimmune Hepatitis

14.5.4 Pemphigus Vulgaris

14.5.5 Allergy and Asthma

14.6 Future Prospects of Treg Cell Therapy

15. GLOBAL CELL THERAPY MARKET DYNAMICS

15.1 Market Drivers

15.2 Commercial Challenges

16. GLOBAL CELL THERAPY MARKET FUTURE PROSPECTS

17. MARKETED CELL THERAPIES CLINICAL INSIGHT BY COMPANY & INDICATION

17.1 Tisagenlecleucel (Kymriah)

17.2 Axicabtagene Ciloleucel (Yescarta)

17.3 Allogeneic Cultured Keratinocytes And Fibroblasts (Gintuit)

17.4 Adipose Stem Cell Therapy (Adipocell (Anterogen), Cupistem & Queencell)

17.5 Tonogenchoncel-L (INVOSSA-K inj)

17.6 Mesenchymal Stem Cell Therapies (Stempeucel)

17.7 Remestemcel-L (Prochymal & TEMCELL HS Inj.)

17.8 Sipuleucel-T (Provenge)

17.9 Autologous Mesenchymal Stem Cell Therapy - Pharmicell

17.10 Autologous Cultured Chondrocytes (MACI)

17.11 Autologous Cultured Chondrocytes (Chondrotransplant DISC)

17.12 Autologous Corneal Epithelial Stem Cell Therapy (Holoclar)

17.13 Nalotimagene Carmaleucel (Zalmoxis)

17.14 Mesenchymal Stem Cell Therapy For Cartilage Repair (Cartistem)

17.15 Autologous Chondrocyte Implant - TETEC

17.16 Muscle-Derived Autologous Stem Cell Therapy (MyoCell)

- 17.17 Human Skin Replacement (CellSpray)
- 17.18 Leukocyte Cell Therapy (CureXcell)
- 17.19 Autologous Cultured Chondrocyte Implant (Carticel)
- 17.20 Azficel-T (Laviv)
- 17.21 Autologous Cultured Chondrocytes (CHONDRON)
- 17.22 Autologous Chondrocytes (BioCart)
- 17.23 Amniotic Cell Therapy (NuCel)
- 17.24 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical
- 17.25 Autologous Cultured Myoblasts And Fibroblasts (Urocell)

18. GLOBAL CELL THERAPY CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

- 18.1 Research
- 18.2 Preclinical
- 18.3 Clinical
- 18.4 Phase-0
- 18.5 Phase-I
- 18.6 Phase-I/II
- 18.7 Phase-II
- 18.8 Phase-II/III
- 18.9 Phase-III
- 18.10 Preregistration
- 18.11 Registered

19. COMPETITIVE LANDSCAPE

- 19.1 Athersys Inc.
- 19.2 Baxter Healthcare Corporation
- 19.3 Bone Therapeutics
- 19.4 Celgene Corporation
- 19.5 Cell Medica
- 19.6 Cellerant Therapeutics
- 19.7 FibrocellScience
- 19.8 Genzyme Corporation
- 19.9 Green Cross Cell
- 19.10 Histogenics Corporation
- 19.11 Intrexon Corporation
- 19.12 Intercytex

- 19.13 ISTO Biologics
- 19.14 Macrocare
- 19.15 Mesoblast
- 19.16 Molmed
- 19.17 Nuo Therapeutics Inc
- 19.18 OmniCyt
- 19.19 Opexa Therapeutics
- 19.20 Organogenesis
- 19.21 Pharmicell
- 19.22 TCA Cellular Therapy
- 19.23 Stem Cell Inc.
- 19.24 Teva Pharmaceuticals
- 19.25 Tigenix
- 19.26 Vericel Corporation

List Of Figures

LIST OF FIGURES

- Figure 1-1: Cell Therapy Pathway
- Figure 1-2: Evolution of Cell Therapy
- Figure 2-1: Types of Cell Therapy
- Figure 2-2: Steps in Allogeneic Cell Therapy
- Figure 2-3: Steps in Autologous Cell Therapy
- Figure 2-4: Steps in the Derivation of Human Embryonic Stem Cells
- Figure 2-5: Cardinal Neural Stem Cell Properties
- Figure 2-6: Mesenchymal Stem Cells Therapy Process
- Figure 3-1: Cell Therapy Mechanism
- Figure 4-1: Centralized Manufacturing Model
- Figure 4-2: Near Patient Manufacturing Model
- Figure 5-1: Major Steps in Cell Therapy
- Figure 5-2: Global- Expected Aging Population of 60+ (Billion), 2015 & 2050
- Figure 5-3: Advantages of Cell Therapy as a Rejuvenation Therapy
- Figure 6-1: Advantages of Personalized Cell Therapy
- Figure 6-2: Mesenchymal Stem Cells (MSCs) in Autism Spectrum Disorder (ASD) Treatment
- Figure 6-3: Steps of iPSC Transplantation
- Figure 7-1: Global - Mortality Caused by Non Communicable Disease (%), 2018
- Figure 7-2: Cell Therapy for Cardiovascular Disease
- Figure 7-3: Overview of Stem Cell Therapy in Cardiovascular Disease
- Figure 7-4: Cell Therapy in Neurological Disorders
- Figure 7-5: Cell Therapy in Treatment of Alzheimer's disease
- Figure 7-6: Cell Therapy in Diabetes
- Figure 8-1: Cell Therapy- The Final Therapeutic Pillar of Healthcare
- Figure 8-2: Global - Cell Therapy Market (US\$ Billion), 2018 - 2026
- Figure 8-3: Process for Conventional Drug Delivery
- Figure 8-4: Process for Induced Pluripotent Stem Cell Based Drug Delivery
- Figure 8-5: Global- Induced Pluripotent Stem Cell Therapy Market (US\$ Million), 2018 - 2026
- Figure 8-6: Steps involved in Bone Marrow Transplant
- Figure 8-7: Global - Cell Therapies Clinical Pipeline by Phase (%), 2019 till 2026
- Figure 8-8: Global - Cell Therapies Clinical Pipeline by Phase (Number), 2019 till 2026
- Figure 8-9: Global - Cell Therapies Clinical Pipeline by Region (Number), 2019 till 2026
- Figure 8-10: Global - Cell Therapies Clinical Pipeline by Region (Number), 2019 till

2026

Figure 8-11: Global - Cell Therapies Clinical Pipeline by Company (Number), 2019

Figure 8-12: Global - Cell Therapies Clinical Pipeline by Indication (Number), 2019

Figure 9-1: US – Allocord Infusion per Hour (Millilitres), Adult & Children

Figure 9-2: US – Laviv Average Injection Cost of Initial & Whole Session (US\$),
March'2019

Figure 9-3: US – Maci Cost Comparison over Mosaicplasty & Microfracture (US\$)

Figure 9-4: US – Clevecord Dosage of Nucleated Cells per Killogram (Million) &
Average Cost (US\$)

Figure 9-5: US – Provenge Cost of Single Infusion vs Overall Cost (US\$), July 2017

Figure 9-6: US – Kymriah Average Dosage of CAR positive viable T cells (Paediatric &
Adults), August 2017

Figure 9-7: US – Kymriah Treatment Cost for Leukemia & Lymphomas (US\$), July 2018

Figure 9-8: US – Yescarta Target Dose vs Maximum Dose of CAR-positive viable T
cells, October 2017

Figure 9-9: US - Yescarta & Kymriah Overall Treatment Cost (US\$), April 2018

Figure 9-10: US - Yescarta & Kymriah Estimated Payment Rate by Centers for
Medicare and Medicaid Services (US\$), April, 2018

Figure 9-11: US – Carticel Minimum & Maximum Cost (US\$), October 2017

Figure 10-1: South Korea – Cartistem Dosage (Microlitres per cm²) & Cost (US\$),
October 2017

Figure 10-2: South Korea – Chondron Dosage (Millilitres per Vial) & Cost (US\$), March
2019

Figure 10-3: South Korea - KeraHeal vs KeraHeal-Allo Dosage form (Millilitres Cell
Suspension)

Figure 10-4: South Korea – Cellgram Dosage (Cells per 10 Millilitre) & Cost (US\$),
October 2017

Figure 11-1: Europe – Holoclax Minimum & Maximum Dosage (Cells per cm²) & Cost
(US\$), August' 2017

Figure 11-2: European Union – Yescarta Dosage of CAR-positive viable T cells by Body
Weight

Figure 11-3: European Union - Yescarta & Kymriah Treatment Cost for acute
lymphoblastic leukaemia and diffuse large B-cell lymphoma (US\$), August' 2018

Figure 11-4: Japan - Temcell Dosage of Cells per Killogram Body Weight (Million)

Figure 11-5: Japan – Temcell Total Cost vs Cost per Bag (US\$), October' 2017

Figure 11-6: Australia - Ortho-ACI Constituents of Dulbecco's Modified Eagle Medium
(DMEM) nutrient mixture

Figure 11-7: Australia - Ortho-ACI Average Dose (Million Cells) & Cost of Treatment
(US\$)

- Figure 12-1: Significance of Cell Therapy Market Technology
- Figure 12-2: Drivers for Growth of Cell Therapy in Japan
- Figure 12-3: Criteria Impacting Successful Cell Therapy
- Figure 12-4: China Cell Therapy Market Strategy
- Figure 12-5: Rest of the World – Cell Therapy Clinical Trial by Region (%), 2019
- Figure 13-1: Signaling Pathway in Chronic Lymphocytic Leukemia
- Figure 13-2: Advantages of Treating Rheumatoid arthritis with Umbilical Cord Mesenchymal Stem Cells
- Figure 13-3: Stem Cell Therapy for the Treatment of Male Infertility
- Figure 13-4: Cell Therapy for Patients with Angina
- Figure 13-5: Benefits of Stem Cell Therapy in Aesthetic Purposes
- Figure 14-1: Working of CD4+ & CD25+ Regulatory T-Cell
- Figure 14-2: Mechanism of Action of Treg Cell
- Figure 14-3: Therapeutic Action of Treg Cell
- Figure 14-4: Future Applications of Treg Cells
- Figure 15-1: Global – Key Factors Driving the Cell Therapy Market
- Figure 15-2: Global - Cell Therapy Market Challenges
- Figure 16-1: Growth Opportunities for Cell Therapy
- Figure 19-1: Bone Therapeutics Clinical Pipeline
- Figure 19-2: Celgene Clinical Pipeline
- Figure 19-3: Cell Medica Therapeutics Clinical Pipeline
- Figure 19-4: Cellerant Therapeutics Clinical Pipeline
- Figure 19-5: Fibrocell Science Clinical Pipeline
- Figure 19-6: Intrexon Clinical Pipeline
- Figure 19-7: Mesoblast Clinical Pipeline
- Figure 19-8: Molmed Clinical Pipeline
- Figure 19-9: Tigenix Clinical Pipeline
- Figure 19-10: Vericel Corporation Clinical Pipeline

List Of Tables

LIST OF TABLES

Table 2-1: Difference between Allogeneic & Autologous Cell Therapy

Table 5-1: Difference between Cell Therapy & Conventional Therapy

Table 13-1: Targeted Therapy in Patients with Chronic Lymphocytic Leukemia

Table 13-2: Targeted Therapy in Patients with Chronic Lymphocytic Leukemia

Table 13-3: Results of Phase I-II Trials of Adoptive Cell Therapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant

Table 14-1: Functions of Effector T-Cell & Treg Cell

COMPANIES MENTIONED

Athersys Inc., Baxter Healthcare Corporation, Bone Therapeutics, Celgene Corporation, Cell Medica, Cellerant Therapeutics, FibrocellScience, Genzyme Corporation, Green Cross Cell, Green Cross Cell, Intrexon Corporation, Intercytex, ISTO Biologics, ISTO Biologics, ISTO Biologics, Molmed, Nuo Therapeutics Inc, OmniCyte, Opexa Therapeutics, Organogenesis, Pharmicell, TCA Cellular Therapy, TCA Cellular Therapy, Teva Pharmaceuticals, Tigenix & Vericel Corporation

I would like to order

Product name: Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026

Product link: <https://marketpublishers.com/r/G66100CFD5EEN.html>

Price: US\$ 2,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G66100CFD5EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970